Results 81 to 90 of about 22,676 (187)

A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms [PDF]

, 2011
Background: Alterations in the DNA methylation pattern are a hallmark of leukemias and lymphomas. However, most epigenetic studies in hematologic neoplasms (HNs) have focused either on the analysis of few candidate genes or many genes and few HN entities,
Agirre, Xabier, Alvarez, Sara, Ammerpohl, Ole, Bibikova, Marina, Brüggemann, Monika, Bug, Stefanie, Calasanz, Maria J., Cruz Cigudosa, Juan, Deckert, Martina, Dreyling, Martin, Du, Ming Q., Dyer, Martin J. S., Dürig, Jan, Fan, Jian-Bing, Gesk, Stefan, Haferlach, Claudia, Hansmann, Martin-Leo, Harder, Lana, Hartmann, Sylvia, Klapper, Wolfram, Küppers, Ralf, Martin-Subero, Jose Ignacio, Montesinos-Rongen, Manuel, Nagel, Inga, Pott, Christiane, Prosper, Felipe, Richter, Julia, Román-Gómez, José, Seifert, Marc, Siebert, Reiner, Stein, Harald, Suela, Javier, Trümper, Lorenz, Vater, Inga, Wickham-Garcia, Eliza   +34 more
core  

Navigating through uncertainty—Experience from the UK national VEXAS MDT

British Journal of Haematology, EarlyView.
Summary The objective of this study was to describe the establishment, structure and influence of the United Kingdom national multidisciplinary team (MDT) for vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic (VEXAS) syndrome and to assess its clinical outputs and perceived value among participating clinicians.
Daniel Pietsch, Austin Kulasekararaj, Sinisa Savic, on behalf of VEXNET‐UK MDT, Adam Al‐Hakim, Tanya Basu, Catherine Cargo, Onima Chowdhry, James Galloway, Eiphyu Htut, Stephen Jolles, Arvind Kaul, Helen Lachmann, Calman A. MacLennan, Anoop Mistry, Elspeth Payne, James Poulter, Farzana Rahman, Manoj Raghavan, Rachel Tattersall, Roochi Trikha, Villyn Yong, Taryn Youngstein, Anna Babb, Celia Beynon, Sarah Bingham, Nuno Borges, Jenny Bosworth, Carlos Campani, Marian Chan, Shikha Chattree, Niall Conlon, Robert Corser, Elena Ganendra, Paraskevi Gkreka, William Gordon, Elisabeth Grey‐Davies, Joanna Haughton, Simona Huica, Pawel Kaczmarek, Alison Laing, Areti Makrygeorgou, Susanna Mathew, Jill Mccormick, Muhammad Mohsin, Vidhya Murthy, Sateesh Nagumantry, Ognjenka Savanovic‐Abel, Shaun Smale, Alex Sternberg, Rosemary Waller, Sarah Westbury   +51 more
wiley   +1 more source

Multiplexed Transcriptomics for Screening Drug Combinations and Defining the Mechanism of Action of HCC Therapeutics at Single‐Cell Resolution

Cell Proliferation, EarlyView.
We designed a framework for screening clinical drug combinations with anti‐hepatocellular carcinoma (HCC) activity, comprising four parts: primary screening, single‐cell screening, functional validation, and mechanism research. High‐throughput single‐cell screening identifies HY (HHT and YM155) as a potent anti‐HCC drug combination, validated by in ...
Mengmeng Jiang, Haide Chen, Guoxia Wen, Yuqing Mei, Wenzhao Zhou, Bin Xu, Tingyue Zhang, Guangyan Li, Junqing Wu, Xiaoping Han, Xudong Fu, Guoji Guo, Jingjing Wang   +12 more
wiley   +1 more source

Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts: A Single Technology Appraisal [PDF]

, 2016
Report commissioned by the NIHR HTA ProgrammeThis report was commissioned by the NIHR HTA Programme as project number 15/64 ...
Cooper, C, Hoyle, MW, Mujica-mota, R, Rudin, C, Rule, S, Snowsill, T, Tikhonova, I, Varley-Campbell, J   +7 more
core  

Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS. [PDF]

, 2013
Myelodysplastic syndromes (MDS), clonal hematopoietic stem-cell disorders mainly affecting older adult patients, show ineffective hematopoiesis in one or more of the lineages of the bone marrow. Most MDS are characterized by anemia, and a number of cases
Cocco, Lucio, Faenza, Irene, Finelli, Carlo, Fiume, Roberta, Follo, Matilde Y., Gobbi, Pietro, Manzoli, Francesco A., Marmiroli, Sandra, Martelli, Alberto M., McCubrey, James A., Ramazzotti, Giulia   +10 more
core   +1 more source

Targeting the Menin–KMT2A Axis in Acute Leukemia: From Epigenetic Dependency to Clinical Translation

European Journal of Haematology, EarlyView.
ABSTRACT Acute leukemias characterized by a shared epigenetic dependency on the menin–KMT2A axis rely on aberrant HOX‐driven transcriptional programs that sustain leukemic self‐renewal and impair differentiation. This dependency is most evident in KMT2A‐rearranged and NPM1‐mutated acute myeloid leukemia (AML), but also extends to other HOX‐dependent ...
Antonella Bruzzese, Ernesto Vigna, Enrica Antonia Martino, Santino Caserta, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Mamdouh Skafi, Nicola Amodio, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Demethylating Agents in the Treatment of Cancer

Pharmaceuticals, 2010
Gene silencing resulting from aberrant DNA methylation can lead to tumorigenesis. Therefore, drugs that inhibit or interfere with DNA methylation have been used to reactivate and induce silenced gene re-expression in malignancies.
Paul M. Howell, Jr., Zixing Liu, Hung T. Khong   +2 more
doaj   +1 more source

Myelodysplastic syndromes: Aspects of current medical care and economic considerations in Germany [PDF]

, 2008
Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases mainly affecting older people. The use of an increasing number of therapeutic options depends on a systematic risk stratification of the patients.
Berger, Karin, Gattermann, Norbert, Hofmann, Wolf-Karsten, Meeßen, Axel, Plesnila-Frank, Carlotta, Schmitz, Stephan, Schramm, Wolfgang, Tsamaloukas, Anton, Vollmer, Tanja, Wedding, Ulrich   +9 more
core   +1 more source

Current perspectives on KMT2A fusion proteins and menin inhibition in paediatric acute myeloid leukaemia

The FEBS Journal, EarlyView.
Genetic rearrangements resulting in the expression of KMT2A fusion alleles can lead to dramatic transcriptional disturbances that contribute to the onset of acute leukaemias. Fortunately, menin inhibition has emerged as a promising new class of targeted therapy.
Lydia Elaine Roets, Graeme Greenfield, Katrina Mairead Lappin   +2 more
wiley   +1 more source

The real-world analysis of adverse events with azacitidine: a pharmacovigilance study based on the FAERS and WHO-VigiAccess databases

Frontiers in Pharmacology
BackgroundAzacitidine is used to treat myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). It acts as a cytosine analog and DNA methyltransferase inhibitor, inducing DNA hypomethylation to reverse epigenetic modifications and restore normal ...
Zhaorui Wang, Linlin Guo, Youfu He, Baiquan Zhang, Yang Wang, Juan Ding   +5 more
doaj   +1 more source